The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma

BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive disease without standardized treatment strategies. The efficacy of second-line or beyond immune checkpoint inhibitors (ICIs) has been proven in recent studies, whereas the evidence for first-line immunotherapy for PSC is stil...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Zhimin, Qian, Xiaoying, Liu, Fanrong, Wang, Yong, Yuan, Yong, Fang, Chen, Zhang, Xinwei, Yuan, Shangkun, Chen, Renfang, Yu, Biao, Wang, Tong, Yin, Yan, Li, Yong, Liu, Anwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659892/
https://www.ncbi.nlm.nih.gov/pubmed/36389780
http://dx.doi.org/10.3389/fimmu.2022.956982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659892/
https://www.ncbi.nlm.nih.gov/pubmed/36389780
http://dx.doi.org/10.3389/fimmu.2022.956982

Ejemplares similares